ReviewJournal of veterinary pharmacology and therapeutics2023
Canine and feline P-glycoprotein deficiency: What we know and where we need to go.
Review in Journal of veterinary pharmacology and therapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- ABCB1 Frameshift Deletion in Skye Terriers With Potential Pharmacogenetic Relevance.Animal genetics · 2026Article
- Effects of vitamins A and E on eprinomectin transport in Caco-2 cells.Veterinarni medicina · 2026Article
- Ivermectin Toxicity in Humans and Animals: Clinical Spectrum, Mechanisms, and Management.Journal of applied toxicology : JAT · 2026Review
- A mini-review of chronic suppression of the hypothalamic-pituitary-adrenal axis in animals with P-glycoprotein deficiency.The Journal of small animal practice · 2026Review
- Functional Characterization of the Cat and Dog Wild-Type and Mutant MDR1 Carrier Proteins and Frequency of the MDR1 Gene Mutation in 800 Cats From Germany.Journal of veterinary pharmacology and therapeutics · 2026Article
- Comparison of Human and Canine P-Glycoprotein Substrates at R, P, and H Binding Sites.Journal of veterinary pharmacology and therapeutics · 2026Article
- Iatrogenic doramectin poisoning in newborn beef calves.Veterinary research communications · 2026Article
- Effects of Oral Macrocyclic Lactone Heartworm Preventatives on Retinal Function and Chromatic Pupillary Light Reflex in Healthy Companion Dogs.Veterinary ophthalmology · 2026Article
- The canine blood-brain barrier in health and disease: focus on brain protection.The veterinary quarterly · 2025Review
- Breed-Specific Anaesthetic Mortality in Dogs: Evidence from an Analysis of 55,019 Cases.Animals : an open access journal from MDPI · 2025Article
- Assessment of clinically relevant drugs as feline P-glycoprotein substrates.Frontiers in veterinary science · 2025Article
- Case Report: Adverse reaction to butorphanol in a Collie homozygous for theFrontiers in veterinary science · 2025Article
- Assessment of P-glycoprotein function using canine intestinal organoid-derived epithelial interfaces.Xenobiotica; the fate of foreign compounds in biological systems · 2024Article
- Impact of concerning excipients on animal safety: insights for veterinary pharmacotherapy and regulatory considerations.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2024Review
- Comparative pharmacokinetics of tyrosine kinase inhibitor, lapatinib, in dogs and cats following single oral administration.The Journal of veterinary medical science · 2024Article
- ABCB1 and ABCG2 Regulation at the Blood-Brain Barrier: Potential New Targets to Improve Brain Drug Delivery.Pharmacological reviews · 2023Review
- Canine and feline P-glycoprotein deficiency: What we know and where we need to go.Journal of veterinary pharmacology and therapeutics · 2023Review
- Does grapiprant reduce osteoarthritic pain in dogs?Veterinary evidenceReview
- Inherent P-glycoprotein deficiency and macrocyclic lactone toxicity in an Australian Maine Coon cat homozygous forJFMS open reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2001 the molecular genetic basis of so-called "ivermectin sensitivity" in herding breed dogs was determined to be a P-glycoprotein deficiency caused by a genetic variant of the MDR1 (ABCB1) gene often called "the MDR1 mutation." We have learned a great deal about P-glycoprotein's role in drug disposition since that discovery, namely that P-glycoprotein transports many more drugs than just macrocyclic lactones that P-glycoprotein mediated drug transport is present in more places than just the blood brain barrier, that some cats have a genetic variant of MDR1 that results in P-glycoprotein deficiency, that P-glycoprotein dysfunction can occur as a result of drug-drug interactions in any dog or cat, and that the concept of P-glycoprotein "inhibitors" versus P-glycoprotein substrates is somewhat arbitrary and artificial. This paper will review these discoveries and discuss how they impact drug selection and dosing in dogs and cats with genetically mediated P-glycoprotein deficiency or P-glycoprotein dysfunction resulting from drug-drug interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.